SCHEMBL770874

SCHEMBL770874

CC1CCN(C(=O)CCCS(=O)(=O)N2CCCC3CCCC=C32)CC1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.47
ALDH1A1 P00352 8/20 0.42
LMNA P02545 6/20 0.42
KMT2A Q03164 5/20 0.42
HPGD P15428 4/20 0.42
MEN1 O00255 3/20 0.42
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
MAPT P10636 4/20 0.36
CHRM2 P08172 1/20 0.36
CHRM4 P08173 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
POLB P06746 1/20 0.36
TP53 P04637 1/20 0.34
HTT P42858 1/20 0.34
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770641 0.90 CHRM2 (0.35) NPC1ALDH1A1LMNAKMT2AHPGD
SCHEMBL771132 0.90 POLB (0.40) NPC1ALDH1A1KMT2AHPGDMEN1
SCHEMBL770148 0.90 POLB (0.40) NPC1ALDH1A1KMT2AHPGDMEN1
SCHEMBL770150 0.90 POLB (0.40) NPC1ALDH1A1KMT2AHPGDMEN1
SCHEMBL770606 0.89 KMT2A (0.39) NPC1ALDH1A1KMT2AHPGDMEN1
SCHEMBL772409 0.89 KMT2A (0.50) ALDH1A1LMNAKMT2AHPGDMEN1
SCHEMBL770815 0.87 ALDH1A1 (0.31) NPC1ALDH1A1HPGDRAB9ASMN1; SMN2
SCHEMBL770972 0.85 HDAC1 (0.34) POLB
SCHEMBL771257 0.84 HTR7 (0.35) KMT2AMEN1SMN1; SMN2MAPTCHRM2
SCHEMBL771723 0.84 CHRM2 (0.39) NPC1ALDH1A1KMT2AHPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885ALDH1A1 144/4885LMNA 3155/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885ALDH1A1 142/4885LMNA 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.